Treatment for chronic hives lasting at least 6 weeks may include one or more types of medication, as well as certain ...

In a safety-net hospital lacking allergy/immunology services, most patients with urticaria do not receive ...

Detailed price information for Beone Medicines Ltd (ONC-Q) from The Globe and Mail including charting and trades.

Individuals diagnosed with chronic spontaneous urticaria (CSU) are at a moderately increased risk of multiple cardiovascular ...

Alys Pharmaceuticals has announced the dosing of the first subject in its phase 1/1b trial of ALY-301, a first-in-class mast ...

Launch Dynamix (TM) is an independent service providing monthly benchmarking of newly launched products for the first eighteen months of commercial availability, augmented by a quarterly deep dive ...

Chronic spontaneous urticaria (CSU), marked by unpredictable and often debilitating flare patterns, continues to impose a significant burden on patients and healthcare ...

If over-the-counter antihistamines aren’t effective for you, your doctor may recommend H2 blockers, steroids, biologics, or ...

The FDA rounded out the month with the approval of remibrutinib (Rhapside; Novartis), a highly selective Bruton tyrosine kinase inhibitor (BTKi), for patients with chronic spontaneous urticaria (CSU) ...

The reality of living with chronic hives -- which by definition last for 6 weeks or longer and have no apparent specific trigger -- can be very challenging. About half of people with "chronic ...

Q32025 net revenue of $26.1 million, driven by MIPLYFFA® net revenue of $22.4 millionCompany to host conference call and ...

Differentiated profile of ALY-301 designed to enable chronic dosing in mast cell dependent diseases while avoiding the safety limitations of conventional c-Kit inhibitors -- Multicenter Phase 1/1b ...